Top 10 Companies in the (S)-(-)-3-tert-Butylamino-1,2-propanediol (CAS No. 31315-46-9) Market (2026): Market Leaders Powering Global Pharmaceutical Synthesis

MARKET INSIGHTS

Global (S)-(-)-3-tert-Butylamino-1,2-propanediol (CAS No. 31315-46-9) market size was valued at USD 38.6 million in 2025. The market is projected to grow from USD 41.2 million in 2026 to USD 74.8 million by 2034, exhibiting a CAGR of 6.9% during the forecast period.

(S)-(-)-3-tert-Butylamino-1,2-propanediol is a chiral amino alcohol compound characterized by its specific stereochemical configuration, which makes it a valuable intermediate in the synthesis of beta‑blocker pharmaceuticals. Most notably, it serves as a key building block in the production of (S)-metoprolol, (S)-atenolol, and related cardiovascular drugs. Its high enantiomeric purity and well‑defined reactivity profile make it essential for asymmetric synthesis processes in the pharmaceutical industry.

The market is steadily gaining traction, driven primarily by the growing global demand for enantiopure pharmaceutical intermediates and the expanding cardiovascular therapeutics pipeline. Furthermore, increasing regulatory emphasis on stereoselective drug manufacturing and the shift toward single‑enantiomer drug formulations are reinforcing demand. Key producers operating in the chiral fine chemicals space, including those specializing in asymmetric synthesis and contract pharmaceutical manufacturing, continue to expand their portfolios to meet evolving industry requirements.

(S)-(-)-3-tert-Butylamino-1,2-propanediol (CAS No. 31315-46-9) Market – View in Detailed Research Report

Top 10 Companies in the Market (2026)

1. Capot Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Pharmaceutical‑grade chiral intermediates, including (S)-(-)-3‑tert‑butylamino‑1,2‑propanediol with ≥98% ee

Capot Chemical has built a reputation for rigorous quality control and scalable asymmetric synthesis. The company’s proprietary catalytic system reduces reaction time and solvent use, positioning it as a preferred partner for API manufacturers seeking high‑purity building blocks.

Sustainability & Growth Initiatives:

• Implementation of continuous flow reactors to lower energy consumption.
• Partnerships with leading CROs to expand supply for ophthalmic beta‑blockers.
• Investment in green solvent alternatives for downstream purification.

2. PharmaBlock Sciences Co., Ltd.

Headquarters: Guangzhou, China
Key Offering: Custom synthesis of chiral amino alcohols with GMP compliance.

PharmaBlock’s portfolio emphasizes flexibility, offering both bulk and specialty grades. Its in‑house analytical team ensures rapid batch qualification, which is critical for contract manufacturers operating under tight regulatory timelines.

Sustainability & Growth Initiatives:

• Adoption of biocatalytic pathways to reduce carbon footprint.
• Expansion of production capacity to meet rising generic market demand.
• Engagement with academic institutions for joint R&D on chiral resolution.

3. BOC Sciences

Headquarters: San Francisco, United States
Key Offering: High‑purity chiral intermediates for API development and R&D.

BOC Sciences focuses on delivering technical grade material for research labs and early‑stage drug discovery. Its robust supply chain and ISO 9001 certification make it a trusted partner for biotech firms exploring novel beta‑adrenergic modulators.

Sustainability & Growth Initiatives:

• Implementation of a closed‑loop water system in production.
• Collaboration with U.S. FDA to streamline regulatory approval pathways.
• Development of scalable asymmetric synthesis modules for high‑volume production.

4. Biosynth

Headquarters: Basel, Switzerland
Key Offering: Catalog compounds for R&D and custom synthesis services.

Biosynth’s expertise lies in rapid, small‑batch production, catering to academic and biotech research. Its strong analytical capabilities allow precise determination of ee and impurity profiles, which is essential for early‑stage development.

Sustainability & Growth Initiatives:

• Use of renewable feedstocks in synthesis.
• Participation in EU REACH compliance programs.
• Investment in enzyme‑based chiral resolution to reduce waste.

5. Hairui Fine Chemical Co., Ltd.

Headquarters: Nanjing, China
Key Offering: Bulk supply of (S)-(-)-3‑tert‑butylamino‑1,2‑propanediol with GMP certification.

Hairui Fine Chemical leverages large‑scale production to deliver cost‑effective solutions for generic manufacturers. Its focus on process optimization has enabled consistent optical purity across large batches.

Sustainability & Growth Initiatives:

• Implementation of energy‑efficient reactor designs.
• Strategic sourcing of low‑impact raw materials.
• Collaboration with local universities to train the next generation of chiral chemists.

6. Finetech Industry Limited

Headquarters: Shenzhen, China
Key Offering: High‑purity chiral intermediates for both pharmaceutical and fine‑chemical markets.

Finetech emphasizes rapid turnaround times for custom orders, making it attractive to CROs and small‑to‑mid‑size pharma companies. Its proprietary chiral catalysts reduce reaction steps, improving yield and purity.

Sustainability & Growth Initiatives:

• Adoption of solvent‑free reaction protocols.
• Investment in digital supply‑chain tracking for traceability.
• Expansion of capacity to support emerging generic markets in Asia.

7. Shanghai AsentChem Co., Ltd.

Headquarters: Shanghai, China
Key Offering: GMP‑grade chiral intermediates with rapid batch qualification.

AsentChem’s focus on high‑throughput synthesis has positioned it as a key supplier for large‑volume API production. The company’s analytical suite provides real‑time ee monitoring, ensuring consistent product quality.

Sustainability & Growth Initiatives:

• Integration of renewable energy sources in manufacturing.
• Development of modular synthesis units for flexible production scaling.
• Collaboration with international regulatory bodies to streamline approval processes.

8. Enamine Ltd.

Headquarters: Kyiv, Ukraine
Key Offering: Pharmaceutical‑grade chiral intermediates with emphasis on cost efficiency.

Enamine serves a broad portfolio of API manufacturers, providing both bulk and specialty grades. Its focus on process economics has made it an attractive partner for cost‑sensitive generic producers.

Sustainability & Growth Initiatives:

• Implementation of waste‑reduction protocols across production lines.
• Investment in green chemistry training for staff.
• Partnerships with European CROs to expand market reach.

9. Apollo Scientific Ltd.

Headquarters: London, United Kingdom
Key Offering: High‑purity chiral intermediates for research and early‑stage development.

Apollo Scientific’s reputation for analytical precision and rapid delivery makes it a preferred supplier for biotech firms exploring novel therapeutic targets. Its strong compliance framework aligns with stringent EU regulations.

Sustainability & Growth Initiatives:

• Adoption of low‑solvent, high‑yield processes.
• Collaboration with UK universities on chiral synthesis research.
• Implementation of ISO 14001 environmental management system.

10. Triveni Interchem Pvt. Ltd.

Headquarters: Bangalore, India
Key Offering: Custom synthesis of chiral intermediates with emphasis on rapid scale‑up.

Triveni Interchem has positioned itself as a go‑to partner for Indian generic manufacturers, offering flexible production schedules and competitive pricing. Its focus on local sourcing has reduced lead times for raw materials.

Sustainability & Growth Initiatives:

• Implementation of energy‑efficient manufacturing processes.
• Partnerships with Indian regulatory agencies to expedite approvals.
• Investment in local talent development for chiral chemistry.

---

Download FREE Sample Report: (S)-(-)-3-tert-Butylamino-1,2-propanediol (CAS No. 31315-46-9) Market – View in Detailed Research Report

Get Full Report: (S)-(-)-3-tert-Butylamino-1,2-propanediol (CAS No. 31315-46-9) Market – View in Detailed Research Report

---

Market Outlook (2026‑2034)

Over the next decade, the demand for enantiopure intermediates will continue to rise, driven by the maturation of generic markets and the expansion of beta‑blocker therapeutics. The projected growth to USD 74.8 million by 2034 reflects a steady increase in both volume and value, as manufacturers prioritize high‑purity materials to meet stringent regulatory expectations. Companies that invest in scalable, green synthesis platforms will be best positioned to capture market share, particularly in regions where generic drug production is expanding rapidly.

Future Trends

• Adoption of continuous flow and micro‑reactor technologies to enhance throughput and reduce waste.
• Increased focus on biocatalysis and enzyme‑based resolution to lower energy consumption and improve ee.
• Growing importance of sustainability metrics in supplier selection, driving demand for low‑carbon manufacturing processes.
• Expansion of the ophthalmic beta‑blocker segment as generics enter key markets, creating new supply‑chain opportunities.
• Emerging research into chiral auxiliary applications, broadening the use of (S)-(-)-3‑tert‑butylamino‑1,2‑propanediol beyond traditional beta‑blockers.